HOME >> BIOLOGY >> NEWS
A humble aquarium fish may be the key to new therapies for birth defects

/p>

"The fact that injecting the human gene can rescue the zebrafish embryo is also an example of gene therapy that works really well, at least temporarily in the fish," adds Solnica-Krezel.

The zebrafish also makes it possible to pursue another, even more promising approach for developing a treatment for Menkes: Testing hundreds or thousands of compounds to see if any can restore proper copper-handling in Calamity mutants. If such a drug can be found, it would be a strong candidate for treating the disorder in human embryos.

"The zebrafish is the first animal model that allows us to watch the process of early vertebrate development and manipulate it. There is no reason why the same approach that we have used with copper cannot work for other nutrients as well," said Gitlin.

In fact, applying this approach to other nutrients and other types of birth defects is the goal of the Children's Discovery Institute, a major new initiative that Gitlin is heading as a joint venture between the St. Louis Children's Hospital and Washington University.


'"/>

Contact: David F. Salisbury
david.salisbury@vanderbilt.edu
615-343-6803
Vanderbilt University
8-Aug-2006


Page: 1 2 3 4

Related biology news :

1. Newly discovered fish named after New York aquarium biologist
2. New asthma gene could lead to new therapies
3. Scientists decode RNA mystery, will help aim drug therapies
4. Genomic signatures identify targeted therapies for lung cancer
5. Existence of muscle-building stem cells points to regenerative therapies for muscular disease
6. Antibody-based therapies effective at controlling malaria
7. Preterm infants with RDS -- surfactant replacement therapies improves neonatal survival
8. UBC discovery may lead to smart therapies for breast, ovarian cancer
9. NDDO and ESMO joined by US National Cancer Institute in conferences on targeted cancer therapies
10. U of MN adult stem cell research shows promise for transplant therapies
11. Boost for new cancer therapies

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: humble aquarium fish may the key new therapies for birth defects

(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
(Date:5/27/2015)... , May 27, 2015  Two years after its ... hackers and citizen scientists, Oakland -based ... campaign promoting its mission to democratize science through a ... Photo ... Based out of the new ...
(Date:5/27/2015)... 2015 ­ Caris Life Sciences®, a leading ... medicine, today announced it has appointed the Levine Cancer ... excellence site in the Caris Centers of Excellence for ... Institute is one of the largest cancer care providers ... cancer patients annually. Derek Raghavan , M.D., Ph.D., ...
(Date:5/26/2015)... , Kalifornien und HILDEN, Deutschland, May 26, ... Clinical Insight ®   ... und die Erstellung dazugehöriger Berichte; Vorstellung auf ... QIAGEN N.V. (NASDAQ: QGEN ... die Markteinführung von QIAGEN Clinical Insight ® ...
(Date:5/26/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... modernized traditional Chinese medicine (mTCM), branded generics and active ... of Shareholders for fiscal year ended June 30, 2014 ... office located in Chengdu, China ... in Chengdu, China ) on May ...
Breaking Biology Technology:East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3
Cached News: